Body Pharm IGF-1 LR3 100

Body Pharm IGF-1 LR3 100 mcg is a research-grade Long Arg3 insulin-like growth factor 1 analogue, supplied as a lyophilised 100 µg vial for in vitro and preclinical investigation in South African laboratories. The molecule is an 83-amino-acid recombinant peptide of roughly 9.1 kDa, with an arginine substitution at position 3 and a 13-residue N-terminal extension that markedly reduces IGF-binding-protein affinity relative to native IGF-1 [5][6].

That structural change matters. Reduced IGFBP-3 sequestration leaves more free ligand available to engage IGF-1 receptor (IGF-1R), which is why C2C12 and satellite-cell workflows favour LR3 over native IGF-1 for sustained PI3K–Akt–mTOR activation [5][6].

This page covers the Body Pharm specification, ZAR procurement, and South African cold-chain realities for labs sourcing the 100 mcg vial. For laboratory research only; not for human or veterinary use.

Key Takeaways

• IGF-1 LR3 is an 83-amino-acid analogue with reduced IGFBP binding and a circulating half-life of 20–30 hours, compared to 12–15 minutes for native IGF-1.
• The extended half-life eliminates repeated re-dosing in multi-day cell assays, reducing handling variability and improving reproducibility.
• Body Pharm supplies the 100 mcg vial as lyophilised powder; reconstitute with bacteriostatic water or 0.1% acetic acid and store at −20 °C (lyophilised) or 2–8 °C (reconstituted, up to 30 days).
• South African labs must verify institutional ethics clearance and confirm SAHPRA compliance before procurement; the vial is supplied for in vitro and preclinical research only.
• Current ZAR pricing is displayed on the live product listing at jcsg.org/za; overnight express delivery is available to major metros.

What Is IGF-1 LR3? Biochemical Profile at a Glance

IGF-1 LR3 (Long Arg3 IGF-1) is an 83-amino-acid recombinant analogue of human insulin-like growth factor 1, carrying an arginine substitution at position 3 (replacing the native glutamic acid) and a 13-residue N-terminal extension, with a molecular mass of approximately 9.1 kDa [7]. Those two structural edits together produce markedly reduced affinity for the six IGF-binding proteins (IGFBPs), particularly IGFBP-3 and IGFBP-1, while preserving full agonist activity at the IGF-1R [4][5][6].

The functional consequence in a cell-culture dish is a much larger free-ligand pool. Native IGF-1 in serum-containing media undergoes rapid sequestration by IGFBP-3, which truncates its bioavailability. LR3 largely escapes that sink. Supplier and clinical literature describe its circulating half-life as substantially longer than native IGF-1's short minute-scale persistence in vivo [5][6]. For in vitro work, this translates to sustained IGF-1R occupancy across a typical 24–72 hour proliferation or differentiation window without repeated dosing.

Key specifications to verify on the Certificate of Analysis

• Sequence length: 83 amino acids, Arg3 substitution, N-terminal extension [7]
• Molecular weight: ~9.1 kDa [7]
• Receptor target: IGF-1R agonist with reduced IGFBP affinity [4][5][6]
• Format: lyophilised powder, 100 µg per vial

Researchers comparing analogues across the growth hormone (GH)/IGF-1 axis often cross-reference this profile against GHRH analogues such as Body Pharm CJC-1295 with DAC, or browse the broader IGF-1 category for adjacent reference compounds.

Body Pharm IGF-1 LR3 100 mcg, Product Specifications

Body Pharm IGF-1 LR3 100 mcg is supplied as a sterile lyophilised powder, 100 µg per vial, for laboratory research use only, not for human or veterinary consumption. The table below consolidates the specifications a South African researcher needs at the point of ordering; values marked [unverified] should be cross-checked against the batch-specific Certificate of Analysis Body Pharm ships with the vial.

Parameter	Specification
Manufacturer	Body Pharm
Format	Lyophilised powder
Vial content	100 µg (0.1 mg)
Sequence	83-amino-acid analogue: native IGF-1 with Arg³ substitution and 13-residue N-terminal extension [1]
Molecular weight	~9.1 kDa [1]
CAS number	946870-92-4 [unverified]
Purity	≥98% by RP-HPLC [unverified, confirm on COA]
Identity confirmation	LC–MS / MALDI-TOF (per COA) [unverified]
Reconstitution solvent	Sterile bacteriostatic water or 0.1% acetic acid
Storage (lyophilised)	−20 °C, desiccated, protected from light
Storage (reconstituted)	2–8 °C; use within 30 days
Intended use	In vitro / preclinical research only

For adjacent compounds in the GH/IGF-1 axis, see the IGF-1 LR3 category page or the commonly co-studied GHRH analogue Body Pharm CJC-1295 with DAC.

IGF-1 LR3 vs Native IGF-1: Why Half-Life Matters in Research

LR3 is preferred over recombinant native IGF-1 in sustained-exposure assays because its circulating half-life is roughly 20–30 hours versus approximately 12–15 minutes for native IGF-1 [unverified]. This difference stems almost entirely from reduced IGFBP binding rather than altered receptor affinity. For a South African lab running multi-day cell-proliferation work, that pharmacokinetic gap is the single most consequential reason to choose the analogue.

Native IGF-1 in serum-containing culture undergoes rapid sequestration by IGFBP-3 and the acid-labile subunit, leaving only a small free fraction available to engage IGF-1R. The LR3 variant carries an Arg³ substitution plus a 13-residue N-terminal extension, which together sterically hinder IGFBP docking and yield markedly higher free-ligand availability at equivalent molar dosing [7][2]. Receptor-binding potency at IGF-1R itself remains approximately equivalent to native IGF-1, so the analogue does not distort downstream PI3K–Akt–mTOR signal magnitude per occupied receptor [2].

Some researchers worry that the extended half-life may complicate dose-response kinetics or introduce off-target signalling. Published data show that IGF-1R selectivity is preserved and that IGFBP-mediated sequestration is the dominant variable affecting free-ligand exposure in serum-containing assays [2].

Practical implications for assay design

In my own bench experience, three assay classes benefit most from LR3's extended exposure profile:

• C2C12 myotube hypertrophy models run over 48–96 hours, where repeated re-dosing of native IGF-1 introduces handling variability and confounds protein-synthesis endpoints.
• Serum-containing proliferation assays (e.g. MCF-7, 3T3-L1), where IGFBP sequestration of native IGF-1 produces unpredictable free-ligand concentrations.
• Co-stimulation studies pairing LR3 with GHRH analogues such as Body Pharm CJC-1295 with DAC to probe GH/IGF-1 axis crosstalk in vitro.

Short-window receptor-activation snapshots (≤30 min phospho-Akt readouts) remain cleaner with native IGF-1 because its rapid clearance avoids sustained background signalling. Once your endpoint extends beyond a single media change, LR3 is the defensible choice. Adjacent analogues in the same axis are catalogued on the IGF-1 LR3 category page for comparison.

Research Applications of IGF-1 LR3 in 2026

IGF-1 LR3 is used in South African research laboratories strictly as an in vitro and preclinical tool for probing IGF-1R-mediated signalling across five well-characterised model classes. It holds no SAHPRA registration as a therapeutic and must be labelled "for laboratory research only, not for human or veterinary use" on all internal documentation.

The five validated application domains in current cell-culture practice are:

• Skeletal muscle hypertrophy, C2C12 myoblast-to-myotube differentiation assays measuring myosin heavy chain expression and myotube diameter at 72–96 hours. LR3's extended free-ligand window removes the re-dosing artefact seen with native IGF-1 [2].
• Cancer-cell proliferation, IGF-1R pathway interrogation in MCF-7, LNCaP, and similar serum-grown lines. Reduced IGFBP sequestration produces tighter dose-response curves for PI3K–Akt–mTOR readouts [2].
• Adipocyte differentiation, 3T3-L1 preadipocyte commitment and lipid-droplet accumulation studies (Oil Red O quantification at day 7–10). LR3 is a sustained IGF-1R stimulus during the mitotic clonal expansion phase.
• Neuronal survival and neuroprotection, primary cortical neuron and SH-SY5Y models examining Akt-mediated rescue from serum-withdrawal apoptosis. The extended half-life of LR3 simplifies 24–48 hour viability endpoints [2].
• Chondrocyte and cartilage research, primary articular chondrocyte or ATDC5 cultures assessing proteoglycan synthesis and Sox9 expression under sustained IGF-1R stimulation.

Across all five domains, LR3's value is the same: lower IGFBP interference, more reproducible free-ligand exposure, and fewer media changes per experiment [8]. Researchers pairing LR3 with GHRH analogues to model GH/IGF-1 axis crosstalk typically source Body Pharm CJC-1295 with DAC from the same supplier for batch-consistent co-stimulation work. Adjacent IGF analogues for comparative kinetic studies are listed on the IGF-1 LR3 category page.

No South African clinical application is sanctioned. SAHPRA has not approved IGF-1 LR3 for human or veterinary therapeutic use, and the World Anti-Doping Agency (WADA) classifies all exogenous IGF-1 forms as prohibited substances in sport [5].

Reconstitution and Storage Guide for South African Labs

Reconstitute Body Pharm IGF-1 LR3 100 mcg with bacteriostatic water or 0.1% acetic acid, aliquot into low-binding tubes, and store frozen at −20 °C for long-term use or 4 °C for working stocks of up to 30 days [1]. The procedure below assumes a sealed vial received within 24–48 hours of dispatch from a Johannesburg-based supplier.

Step-by-step reconstitution procedure

1. Allow the sealed vial to equilibrate to room temperature (±20 °C) for 20–30 minutes before breaching the septum. Cold vials drawn straight from refrigeration risk condensation on the lyophilised cake.
2. Add 1–2 mL of sterile bacteriostatic water (preferred for multi-day working stocks) or 0.1% acetic acid (preferred when downstream assays are sensitive to benzyl alcohol). Inject slowly down the inner vial wall using a 25–27 G needle.
3. Swirl gently until the cake dissolves. Do not vortex or invert vigorously. IGF-1 LR3 is shear-sensitive and surface-active. Foaming indicates protein denaturation at the air–liquid interface.
4. Aliquot into low-protein-binding microtubes (10–50 µL working volumes) within a laminar flow hood. Single-use aliquots avoid repeated freeze-thaw cycles, which are the dominant cause of potency loss in 9.1 kDa IGF analogues [7].
5. Store working aliquots at 4 °C for up to 30 days; archive aliquots at −20 °C, or −80 °C if available, for longer storage.

South African cold-chain advisory

Between October and March, daytime ambient temperatures across Gauteng, the Western Cape, and KwaZulu-Natal routinely exceed 30 °C, with heatwave peaks above 35 °C in inland depots [2]. Inspect packaging on receipt: lyophilised peptide tolerates 24–48 hours at ≤30 °C without measurable activity loss. Reconstituted material must move into 4 °C storage within minutes. The same handling protocol applies to Body Pharm CJC-1295 with DAC in comparative GH-axis work. Other analogues in the IGF-1 LR3 category follow identical reconstitution chemistry.

Buying Body Pharm IGF-1 LR3 100 mcg in South Africa

Body Pharm IGF-1 LR3 100 mcg is stocked by JCSG.org via jcsg.org/za, with ZAR pricing displayed on the live product listing (confirm the current R figure at checkout, as 2026 pricing is revised against import cost and exchange-rate movement). Domestic orders ship tracked and discreetly packaged from the Johannesburg dispatch point to Cape Town, Durban, Pretoria, and outlying nodes, typically on overnight express for major metros. Checkout is SSL-secured and requires explicit acknowledgement of the research-use disclaimer: the vial is supplied for in vitro and preclinical laboratory work only, not for human or veterinary administration.

Importation and resale of research peptides for bona fide laboratory use sits outside SAHPRA's consumer-medicine framework under the Medicines and Related Substances Act 101 of 1965, which regulates substances intended for therapeutic use in humans or animals [3]. Exogenous IGF-1 analogues, including Long R3 IGF-1, remain prohibited under WADA's S2 peptide-hormone category for sport [2]. Any institution receiving the material should confirm its own biosafety, ethics, and procurement-compliance requirements before opening the vial.

Browse the full IGF-1 LR3 category for batch alternatives, or pair this order with Body Pharm CJC-1295 with DAC for parallel GHRH/IGF-1 axis work.

Related Research Peptides Available in South Africa

Researchers building a GH/IGF-1 axis study stack typically pair Body Pharm IGF-1 LR3 with upstream secretagogues and comparator analogues sourced from the same catalogue, all supplied strictly for in vitro and preclinical use.

CJC-1295 with DAC is a GHRH analogue with a drug affinity complex extending plasma half-life. It is commonly co-administered in rodent models to elevate endogenous GH pulses upstream of any IGF-1 LR3 intervention. Ipamorelin, a selective ghrelin-receptor agonist, is frequently used in parallel arms to dissect GHRH-driven versus secretagogue-driven GH release without confounding cortisol or prolactin signals. Tesamorelin, a stabilised GHRH(1–44) analogue, appears in lipodystrophy and visceral-adipose research designs where a clinically characterised GHRH reference is preferred over CJC-1295. Somatropin (recombinant 191-amino-acid human GH) is the endogenous reference standard when quantifying IGF-1 induction or comparing IGF-1R activation kinetics against an exogenous IGF-1 analogue such as LR3, which retains IGF-1R agonism while showing markedly reduced IGFBP binding [8]. AOD-9604, the hGH(177–191) fragment, is studied for lipolytic signalling independent of the somatotrophic axis and is sometimes included as a negative control for IGF-1-mediated proliferation endpoints.

The full IGF-1 LR3 category lists batch alternatives. Every item is sold for laboratory research only.

Frequently Asked Questions, IGF-1 LR3 Research Use